Johnson & Johnson's First-Quarter 2018 Earnings Review
We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.
Sunday, April 22, 2018
Johnson & Johnson's First-Quarter 2018 Earnings Review
Johnson & Johnson's First-Quarter 2018 Earnings Review
We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.
Related Posts:
Broadcom's ambitious chief will shift target after Qualcomm halt: analysts- Q&A: World Trade Organization's role in Trump trade tussle
- Stock futures jump after data dims fears of inflation overheating
- U.S. consumer prices slow in February; rents moderate
- Starbucks signs licensing agreement with Brazil private equity firm
0 comments:
Post a Comment